O

Oncovalent Therapeutics

14 employees

Developer of Immuno oncology drugs intended to develop novel therapeutics to inhibit the human oncogene.

Basic info

Industry

biotechnology research

Sectors

Pre-clinical
Small Molecule
Biotechnology
Young
Molecular Biology
Early Stage
Clinical
Oncology
Monoclonal Antibodies
Pharmaceutical
Start Up
Medicinal Chemistry
Southern California
Innovation
Experienced
Energetic
Therapeutics
Drug Development
Immuno Oncology
Targeted Therapies
Entrepreneurial
Cancer

Date founded

2020

Funding rounds raised

O

Oncovalent Therapeutics raised undisclosed on September 9, 2020

Investors: Corner Ventures

FAQ